Moya-Martínez C, Torre-Castro J, Fariña-Sabarís MC, Santiago Sánchez-Mateos D, Eraña-Tomás I, Jo-Velasco M, Requena L. Cutaneous eruption with reactive
endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico-pathologic correlation.
J Cutan Pathol 2021;
48:789-794. [PMID:
33576042 DOI:
10.1111/cup.13981]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Revised: 01/27/2021] [Accepted: 02/05/2021] [Indexed: 12/13/2022]
Abstract
Targeted anticancer therapy is being used with greater frequency and dermatologic toxicities are among the most frequent adverse events of these drugs. However, histopathological features of these adverse events are not yet well characterized. We present two cases of clinically different cutaneous toxicities on two patients with hematologic neoplasia. They were treated with different drugs and in both cases medications shared inhibition of PI3K as mechanism of action. The skin biopsy specimen showed endothelial cell atypia with large nuclei and mitotic figures. To the best of our knowledge, no other cases with these striking histopathologic findings have been reported with PI3K inhibitors or other anticancer targeted therapy.
Collapse